Zhi Tong Cai Jing·2026-01-20 11:40Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of SHR-9839 and HRS-4642, indicating progress in its oncology drug development pipeline [1] Group 1: Drug Development - SHR-9839 is a humanized antibody drug developed by the company, intended for the treatment of advanced solid tumors by blocking two key signaling pathways related to tumor development [1] - The subcutaneous formulation of SHR-9839 has one competitor with the same target already approved globally [1] - HRS-4642 is a KRAS G12D inhibitor developed by the company, formulated as a liposome injection, which specifically binds to KRAS G12D and inhibits the phosphorylation of MEK and ERK proteins [1] - Currently, there are no similar drugs approved for HRS-4642 in both domestic and international markets [1]